Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program
mediaposted on 2022-04-05, 00:50 authored by Adis Journals on behalf of:, Eric L. Simpson, Jonathan I. Silverberg, Audrey Nosbaum, Kevin L. Winthrop, Emma Guttman-Yassky, Karin M. Hoffmeister, Alexander Egeberg, Hernan Valdez, Min Zhang, Saleem A. Farooqui, William Romero, Andrew J. Thorpe, Ricardo Rojo, Susan Johnson
Article full text
For a full list of declarations, including funding
and author disclosure statements, please see the full text online (see “read
the peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2021